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Type 2 diabetes (T2D), a complex and chronic disease
characterized by hyperglycemia, is becoming more prevalent.
It was estimated that 366 million people will be afﬂicted with
diabetes worldwide by 2030 and 95% of them are T2D1. There
mainly are three contributing factors leading to hyperglyce-
mia, including reduction of insulin secretion from pancreatic
b-cells2, decreased tissue sensitivity to insulin and dysregulated
hepatic glucose metabolism. Although many antihyperglyce-
mia drugs have been developed, the therapeutic effects of the
commercially available single target drugs for T2D are
unsatisfactory as those drugs address only a part of the disease
or a speciﬁc stage of T2D, and can induce drug resistance.
Therefore, it is necessary to develop multiple-target hypogly-
cemic drugs with more widespread therapeutic effect.
Glucokinase (GK), a glucose-phosphorylating enzyme and
member of the hexokinase family, is mainly expressed in the liver
and pancreatic b-cells. It is a potential therapeutic targets for
T2D3,4, as activation of GK not only promotes glycogen synthesis
but also enhances insulin secretion from pancreatic b-cells. Hence,
the development of GK activators to lower blood glucose and
normalize insulin secretion is a promising area of current research
for treating T2D. Several groups have described various synthetic
small molecules that act as GK activators (Fig. 1)5.
Peroxisome proliferator-activated receptors (PPARs) exist
as three isoforms (PPARa, PPARb and PPARg) and areFigure 1 Structures of some GK activators reporte
Figure 2 Structures of some PPARg agonists aligand-activated transcription factors that offer a promising
therapeutic approach for metabolic syndrome6. Activation of
PPARg by insulin-sensitizing thiazolidinedione (TZD) drugs7,8
leads to improve insulin action in muscle and liver. Several
groups have described various synthetic small molecules as
PPARg agonists (Fig. 2).
Based on the above understanding of GK and PPARg, a
drug able to simultaneously activate both GK and PPARg
would be expected to have a strong antihyperglycemia effect
by promoting insulin secretion, modulating hepatic glucose
balance, and decreasing insulin resistance.
Our design of compounds with dual action as both GK
activators and PPARg agonists is based on the assembly of
ligand-based pharmacophores. We started from the fusion of a
GK activator 1 reported by Prosidion/OSI, and a PPARg
agonist 7 reported from Dainippon Sumitomo, to form the
compound structure 11 with dual pharmacophores (Fig. 3).
Though these two compounds 1 and 7 are different in shape,
they share the same disubstituted phenyl scaffold. We used the
phenyl-urea structure of GK activator 1 as the parent compound
backbone and added the pharmacophore of 7 and various
nitrogen heteroaromatic groups to it, generating structure 12
with three groups, R1, R2, and R3 that remained modiﬁable.
Based upon this template, a series of phenyl-urea derivatives
were designed, prepared and evaluated for ability to activate GK
and PPARg. Some of these compounds showed potent ability to
activate both GK and PPARg simultaneously.d and their pharmacophores (moieties in blue).
nd their pharmacophores (moieties in blue).
Figure 3 Design strategy for GK/PPARg dual-target ligands.
Scheme 1 Synthesis of compounds 17a–f and 18a–f. Reagents and conditions: (a) K2CO3, DMF, 80 1C, 6 h; (b) MeOH, 10% Pd-C, rt,
6–8 h; (c) R1Br, K2CO3, DMF, 80 1C, 4–8 h; (d) aldehyde, AcOH, EtOH, 70 1C, 4–8 h, and then NaBH4, 60 1C, 10 h and (e) MeCN, 22
or 23, reﬂux.
Scheme 2 Synthesis of compounds 22 and 23. Reagents and conditions: (a) K2CO3, 2-aminothiazole or 2-amino-benzothiazole, MeCN, reﬂux.
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2.1. Chemistry
The phenyl-urea derivatives were synthesized by the routes
shown in Schemes 1–3. Commercially available p-nitrophenol13 was O-alkylated with ethyl 2-bromoacetate in the presence
of K2CO3 in DMF to give nitrobenzene derivatives 14. Aniline
derivative 15 was obtained from reduction of 14, and the
secondary amines 16a–f were prepared by the N-alkylation of
15 with alkylbromide or aldehydes9. Subsequently, the con-
densation of 16a–f with the 4-nitrophenylcarbamate esters of
Scheme 3 Synthesis of compounds 20a–k. Reagents and conditions: (a) CDI, DMAP, DCM, reﬂux; (b) k2CO3, MeOH, H2O, 60 1C.
Table 1 GK activation effect of compounds 17a–f
and GKA22.
Compd. R1 Activation (fold)
a
17a Cyclopropylmethyl 1.2
17b Cyclohexylmethyl 1.0
17c n-Butyl 1.4
17d n-Pentyl 1.8
17e i-Pentyl 1.2
17f 3-Methyl-2-butenyl 1.4
GKA22 1.7
aGK activation (fold) was obtained at a Glc concentration of
4 mM.
Table 2 GK activation effect of compounds 18a–f.
Compd. R1 Activation (fold)
a
18a Cyclopropylmethyl 0.8
18b Cyclohexylmethyl 1.0
18c n-Butyl 1.3
18d n-Pentyl 1.3
18e i-Pentyl 1.2
18f 3-Methyl-2-butenyl 0.8
aGK activation (fold) was obtained at a Glc concentration of
4 mM.
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derivatives 17a–f or 18a–f (Scheme 1). Compounds 22 and 23
were prepared starting from 4-nitrophenyl carbonochloridate
(Scheme 2). The phenyl-urea derivatives 19a–k were prepared
by the three-component condensation of secondary amine 16d,
carbonyldiimidazole, and various 2-amino nitrogen heteroaro-
matics10. Compounds 20a–k were obtained by the hydroliza-
tion of 19a–k in a methanol–water–K2CO3 system (Scheme 3)2.2. In vitro biological activity assay
The in vitro GK activity assay was performed at 37 1C for 60 min
in 96-well plates with a ﬁnal volume of 150 mL reaction mixture
containing 25 mMATP, 1 mMNAD, 2 mMMgCl2, 5 mMDTT,
25 mM KCl, 100 mM Tris–HCl, 4.5 unit/mL glucose 6-phosphate
dehydrogenase, 2 unit/mL recombinant GK, 4 mM glucose and
test compound. After starting the reaction the increase in
absorbance at 340 nm was monitored from 0 to 60 min with a
Bio-TEK microplate reader as a measure of GK activity.
The in vitro activation of GK by the target compounds were
evaluated at a concentration 10 mM, and GKA22, a GK
activator developed by the AstraZeneca11, was used as positive
control. The compounds that showed greatest ability to activate
GK were selected for further study and for their ability to
activate transcription by PPARg in a cell-based assay.
We ﬁrst estimated the ability of compounds 17a–f to activate
GK; these bear a thiazole ring attached to the secondary ureanitrogen. As shown in Table 1, the potency of compounds with
acycloalkyl groups viz 17c–f, was superior to compounds with
cycloalkyl groups viz 17a–b. The potency of compounds with
straight-chain alkyl groups viz 17c–d, was slightly higher than
compounds with branched-chain alkyl groups viz 17e–f. And the
potency of compound with n-pentyl group 17d was the strongest
in Table 1.
Subsequently, the activation of GK by the compounds 18a–f,
bearing a 6-methylbenzothiazole ring replacing the thiazole ring of
17a–f, was evaluated. As shown in Table 2, the potency of
compounds 18a–f was obviously lower than that of the corre-
sponding compounds 17a–f. The similar structure–activity rela-
tionship noted in Table 1 was observed for compounds 18a–f in
Table 2.
As can be seen from Tables 1 and 2, replacing the thiazole ring
of 17a–f with a 6-methylbenzothiazole ring had a detrimental
effect on potency for GK activation, and the potency of 17a–f was
notably increased when R1 was n-pentyl group 17d and 18d,
whether the nitrogen heteroaromatic moiety was thiazole or
6-methylbenzothiazole. Subsequently, with R1 as a n-pentyl group,
we explored the effect of a wide range nitrogen heteroaromatic
groups attached to the secondary urea nitrogen on GK activation
efﬁciency.
As shown in Table 3, the compound 19a with a pyridine
ring and 17d with a thiazole ring were equipotent in GK
activation. The substitution of simple thiazole group led to
obvious reduction of potency, for example 19g–i. And when
R3 was H instead of the ethyl, the same substitution of
thiazole group analogs 20e–g, also displayed less potency than
Table 3 GK activation effect of the compounds 19a–k
and 20a–k.
Compd. R3 R2
Activation
(fold)a
19a Et 1.8
19b Et 1.4
19c Et 0.8
19d Et 1.7
19e Et 1.4
19f Et 1.2
19g Et 1.6
19h Et 1.5
19i Et 1.6
19j Et 1.5
19k Et 1.3
20a H 1.6
20b H 1.7
Table 3 (continued )
Compd. R3 R2
Activation
(fold)a
20c H 1.3
20d H 1.1
20e H 1.6
20f H 1.4
20g H 1.3
20h H 1.2
20i H 1.5
20j H 1.7
20k H 1.6
aGK activation (fold) was obtained at a Glc concentration of
4 mM.
Lijian Zhang et al.592the corresponding compounds 17d and 19g–h. When R2 was a
pyridine derivates group12,13, the simple substitution of pyridine
group, for example 19b–f led to signiﬁcant reduction in or loss of
potency, except compound 19d which contains a 5-
methoxycarbonyl pyridine moiety showing a GK activation fold
of 1.7, similar to the non-substituted pyridine group analog 19a.
Interestingly, when R3 was H the GK activation fold of the high
potency compound 19a was reduced, the corresponding com-
pound 20a was 1.6, and the low potency compounds 19b–c were
increased, with the potency of the corresponding compounds
20b–c was 1.7 and 1.3, respectively. In addition, when R2 was a
benzothiazole derivates group the simply C-6 substitution of a
benzothiazole group also led to slight reduction of potency, for
Table 4 Activation of selected compounds to GK and
PPARg.
Compd. EC1.5 (mM)a PPARg (%)b
17d 79.17 44.6
19a 94.70 41.5
19d 5.35 43.4
19i 68.89 64.1
20e 32.12 50.9
20j 7.52 54.0
20k 6.85 51.2
GKA22 3.50 –
aEC1.5 means the concentration of compounds required to
increase enzyme activity by 50%.
bThe effect of tested compounds on activity of PPARg
transcription at 106 M was evaluated by luciferase reporter
gene assay and presented as activity relative to rosiglitazone.
The activity of rosiglitazone is assigned as 100%.
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the same substitution of benzothiazole group analogs 20j–k,
displayed remarkably improved potency, with GK activation
fold of 1.7 and 1.6, respectively, as compared to that of
corresponding compounds 18d and 19k.
Based on the ability of the targeted compounds to activate
GK, seven potential candidates (activation foldZ1.6) were
selected for further evaluation in the GK enzyme assay
(EC1.5) and a cell-based PPARg transcription assay. As
shown in Table 4, compounds 19d, 20j and 20k not only were
potent GK activators with EC1.5 values of 5.35, 7.52 and
6.85 mM, respectively, similar to that of GKA22, but also
displayed the activity to activate PPARg transcription with a
potency in the range of 43–54% as compared to rosiglitazone.
We also predicted the binding mode for these compounds in the
ligand-binding domains of GK and PPARg respectively by using
the CDOCKER docking program. As shown in Fig. 4A, com-
pound 19d binds at the allosteric site of GK similar to that of other
reported complexes14,15, and forms a bidentate hydrogen bond by
the pyridine N atom and the NH group of the amide with the
backbone NH and carbonyl oxygen of Arg63 on GK. This may
explain its potent ability to activate GK. Meanwhile, Fig. 4B
represents the main interactions between compound 19d and
PPARg. Compound 19d does not form a network of hydrogen
bonds with the side chains of Tyr473, His449, Ser289 and His323
in the polar cavity of the PPARg as rosiglitazone does, but showed
H-bond interactions with Cys285, Ser289, Tyr327 and Ser342. The
absence of strong interactions may explain the signiﬁcant decrease
in the activation of PPARg transcription.3. Conclusion
In summary, a series of phenyl-urea derivatives were designed,
prepared and evaluated for their ability to activate GK and
PPARg. Some of these compounds, for example 19d, 20j and
20k, showed potent activity towards both GK and PPARg, and
the possible binding modes of compounds 19d with GK and
PPARg were predicted by in silico molecular docking. These dual
actions towards GK and PPARg may produce a more wide-
spread therapeutic effect on the hyperglycemia associated with
T2D. The discovery of compounds that act on both targets gives
a new approach to the design of anti-diabetic agents.4. Experimental
All reagents and chemicals were obtained from commercial
suppliers and used as received. Reaction progress was mon-
itored by thin-layer chromatography on Qindao silica gel 60
F-254 with UV detection. Flash column chromatography was
performed on silica gel 60 (200–300 mesh) from Qindao
Haiyang Chemical Factory. 1H NMR spectra were recorded
on a Mercury-300 spectrometer with Chemical shifts in
ppm (d) relative to the solvent signal and coupling constant
(J) values in Hz. HPLC-MS analysis was performed on a
Thermo Finnigan LCQ-Advantage mass spectrometer.
4.1. Ethyl 2-(4-nitrophenoxy) acetate (14).
Anhydrous potassium carbonate (2.5 g, 17.4 mmol) in por-
tions was added to a stirred solution of 4-nitrophenol 13 (2 g,14.4 mmol) and ethyl bromoacetate (2.7 g, 16.2 mmol) in
DMF (20 mL), the reaction mixture was heated at 80 1C for
6 h, then cooled to room temperature and poured into 100 mL
water, extracted with ethyl acetate several times. The com-
bined organic layers were washed with brine, dried on
anhydrous Na2SO4, ﬁltered and evaporated under reduced
pressure to afford 3.08 g of compound 14, yield 95%.4.2. Ethyl 2-(4-aminophenoxy) acetate (15).
A suspension of ethyl 2-(4-nitrophenoxy) acetate 14 (450 mg,
2 mmol) and Pd-C (45 mg) in methanol (15 mL) was treated
with H2 at atmosphere pressure and room temperature for 6–
8 h. The mixture was ﬁltered and concentrated under reduced
pressure to give 378 mg of 15, yield 97%.4.3. General procedure for the preparation of compounds
16a–f.
Method 1: the corresponding alkyl bromides (1 equiv.) was
slowly added to a stirred solution of ethyl 2-(4-aminophenoxy)
acetate 15 (1 equiv.) and anhydrous potassium carbonate
(0.5 equiv.) in dry DMF, and then heated at 80 1C until the
reaction completed. The mixture was diluted with ethyl acetate
and washed with water and brine successively, dried over
anhydrous Na2SO4, ﬁltered and concentrated under reduced
pressure. The residue was puriﬁed by column chromatography
with PE/EtOA as eluent.
Method 2: several drops AcOH and the corresponding
aldehyde (1 equiv.) were added to a stirred solution of ethyl 2-
(4-aminophenoxy) acetate 15 (1 equiv.) in MeOH, and then
heated to 70 1C. When the reaction was completed, NaBH4(3
equiv.) was added and reacted at 60 1C for 10 h, then
evaporated the solvent under reduced pressure. The residue
was diluted with ethyl acetate and washed with water and
brine successively, dried over anhydrous Na2SO4, ﬁltered and
concentrated under reduced pressure. The crude product
obtained was further puriﬁed by column chromatography
with PE/EtOA as eluent.
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4-nitrophenyl-6-methylbenzo[d] thiazol-2-yl-carbamate (23).
4-Nitrophenyl chloroformate (1.2 equiv.) was added to a
stirred mixture of thiazol-2-amine (1 equiv.) and anhydrous
potassium carbonate (0.6 equiv.) in MeCN, then reﬂuxed.
The reaction mixture was concentrated and diluted with ethyl
acetate, washed with water several times. The organic phase
was dried with anhydrous Na2SO4, then ﬁltered, concen-
trated and used in the next step. Use the 6-methylbenzo[d]
thiazol-2-amine instead of thiazol-2-amine and the same
method to give 4-nitrophenyl 6-methylbenzo[d]thiazol-2-yl-
carbamate (23).4.5. General procedure for the preparation of compounds
17a–f and 18a–f.
Intermediates 22 or 23 (1 equiv.) was added to a solution of
16a–f (1.1 equiv.) in MeCN and reﬂuxed. After the reaction
was completed, the reaction mixture was cooled to r.t. and the
solvent was evaporated under reduced pressure. The residue
was then diluted with dichloromethane and washed with water
and brine, dried by anhydrous Na2SO4, ﬁltered and concen-
trated under reduced pressure. The rude product was puriﬁed
by column chromatography to give 17a–f and 18a–f.4.6. General procedure for the preparation of compounds
19a–k and 20a–k.
The hetero-aromatic amine (1 equiv.) and 4-dimethylamino-
pyridine (0.05 equiv.) were added to a stirred solution of 1,10-
carbonyldiimidazole (1.1 equiv.) in anhydrous dichloromethane,
and the reaction was reﬂuxed for 3 h, then cooled to 0 1C, and the
ethyl 2-[4-(pentylmino)phenoxy]acetate (16d) was added in por-
tions, then reﬂuxed until reaction was completed. The mixture was
diluted with dichloromethane, and washed with water and brine,
dried on anhydrous Na2SO4, ﬁltered and concentrated under
reduced pressure. The residue was puriﬁed by column chromato-
graphy to afford compounds 19a–k.
Potassium carbonate (2 equiv.) was added to a solution of the
compounds 19a–k (1 equiv.) in methanol and water (5:1, v/v).
The mixture was heated at 60 1C until the reaction ﬁnished. The
solvent was evaporated under reduced pressure. The residue wasFig. 4 Calculated binding mode of hit compound 19d. The structures
Selected residues are shown as thin sticks (carbons in purple, oxygens
carbons in green, oxygens in red, nitrogens in blue and sulfur in oranacidiﬁed with 1 M HCl, and ﬁltrated, recrystallized to give the
target compounds 20a–k.
4.7. Characterization of new products
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(cyclopropylmethyl)-
3-(thiazol-2-yl)urea(17a): 1H NMR (DMSO-d6, 300 MHz), d:
9.68 (s, 1H, CONH), 7.23 (m, 3H, ArH), 6.97 (m, 3H, ArH),
4.80 (s, 1H, COCH2), 4.18 (q, 2H, J¼6.9 Hz, CH2), 3.52
(d, 2H, J¼6.6 Hz, CH2), 1.22 (t, 3H, J¼6.9 Hz, CH3),
0.89–0.94 (m, 1H, CH¼), 0.34–0.40 (m, 2H, CH2), 0.04–
0.09 (m, 2H, CH2); m/z 376 [MþH]þ; HR-MS calculated for
C18H21N3O4S: m/z 376.1326 [MþH]þ, found 376.1326.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(cyclohexylmethyl)-
3-(thiazol-2-yl)urea(17b): 1H NMR (DMSO-d6, 300 MHz), d:
9.60 (s, 1H, ¼CHNH–), 7.25 (d, 1H, J¼3.3 Hz, ArH), 7.20 (d,
2H, J¼8.7 Hz, ArH), 6.95–6.98 (m, 3H, ArH), 4.80 (s, 1H,
COCH2), 4.18 (q, 2H, J¼7.2 Hz, CH2), 3.53 (d, 2H,
J¼6.9 Hz, CH2), 1.56–1.65 (m, 4H, CH2 2), 1.39 (m,
1H, CH¼), 1.22 (t, 3H, J¼7.2 Hz, CH3), 1.09–1.18 (m, 4H,
CH2 2), 0.88–0.93 (m, 2H, CH2); m/z 418 [MþH]þ; HR-
MS calculated for C21H27N3O4S: m/z 418.179 [MþH]þ, found
418.1795.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-butyl)-3-(thiazol-2-
yl)urea (17c): 1H NMR (DMSO-d6, 300 MHz), d: 7.27 (d, 1H,
¼CHNH), 7.23 (d, 2H, J¼3.6 Hz, ArH), 7.00 (d, 3H, J¼
3.6 Hz, ArH), 4.81 (s, 2H, COCH2), 4.23 (q, 2H, J¼7.2
Hz, OCH2), 3.66 (t, 2H, J¼6.9 Hz, CH2), 1.39 (q, 2H,
J¼6.9 Hz, CH2), 1.301.15 (m, 5H, CH2CH3), 0.91 (t,
3H, J¼7.2 Hz, CH3); m/z 377.1 [MþH]þ; HR-MS calcu-
lated for C18H23N3O4S: m/z 378.1482 [MþH]þ, found
378.1058.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(thiazol-
2-yl)urea (17d): 1H NMR (DMSO-d6, 300 MHz), d: 9.81
(s, 1H, CONH), 7.25 (d, 1H, J¼3.9 Hz, ArH), 7.20 (d, 2H,
J¼8.7 Hz, ArH), 6.95–6.98 (m, 3H, ArH), 4.80 (s, 2H,
COCH2), 4.18 (q, 2H, J¼6.9 Hz, CH2), 3.62 (t, 2H,
J¼7.2 Hz, CH2), 1.40–1.45 (m, 2H, CH2), 1.20–1.24
(m, 7H, CH2 2, CH3), 0.83 (t, 3H, J¼6.9 Hz, -CH3); m/z
392.2 (MþH)þ; HR-MS calculated for C19H25N3O4S: m/z
392.1632 [MþH]þ, found 392.1639.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(i-pentyl)-3-(thia-
zol-2-yl)urea (17e): 1H NMR (DMSO-d6, 300 MHz), d: 9.63
(s, 1H, CONH), 7.247.18 (m, 3H, ArH), 6.97 (m, 2H,
ArH), 4.80 (s, 2H, COCH2), 4.18 (q, 2H, J¼7.2 Hz,of GK (A) and PPARg (B) are displayed as cartoon in off-white.
in red and nitrogen in blue). Coloring for the ligand is as follows:
ge. Predicted H-bonds are shown as white thin lines.
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CH¼), 1.28–1.35 (m, 2H, CH2), 1.21 (t, 3H, J¼6.9 Hz,
CH3), 0.83 (d, 6H, J¼6.6 Hz, CH3 2); m/z 392 [MþH]þ;
HR-MS calculated for C19H25N3O4S: m/z 392.1630 [MþH]þ,
found 392.0625.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(3-methyl-2-butenyl)-
3-(thiazol-2-yl)urea (17f): 1H NMR (DMSO-d6, 300 MHz), d:
9.70 (s, 1H, CONH), 7.24 (d, 1H, J¼3.6 Hz, ArH), 7.16
(d, 2H, J¼8.7 Hz, ArH), 6.94 (m, 3H, ArH), 5.20 (t, 1H,
J¼6.9 Hz, CH¼), 4.79 (s, 2H, COCH2), 4.14–4.24 (m,
4H, CH2 2), 1.62 (s, 3H, CH3), 1.42 (s, 3H, CH3),
1.21 (t, 3H, J¼7.2 Hz, CH3); m/z 390 [MþH]þ; HR-MS
calculated for C19H23N3O4S: m/z 390.1481 [MþH]þ, found
390.1482.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(cyclopropylmet
hyl)-3-(6-methylbenzo[d] thiazol-2-yl)urea (18a): 1H NMR
(DMSO-d6, 300 MHz), d: 10.11 (s, 1H, CONH), 7.58 (s,
1H, ArH), 7.11–7.25 (m, 4H, ArH), 6.96 (d, 2H, J¼8.7 Hz,
ArH), 4.80 (s, 2H, COCH2), 4.18 (q, 2H, J¼7.2 Hz,
CH2), 3.53 (d, 2H, J¼6.9 Hz, CH2), 2.34 (s, 1H,
CH3), 1.22 (t, 3H, J¼6.9 Hz, CH3), 0.89–0.94 (m, 1H,
CH¼), 0.37–0.41 (m, 2H, CH2), 0.04–0.09 (m, 2H, –
CH2–); m/z 440.2 [MþH]þ; HR-MS calculated for
C23H25N3O4S: m/z 440.1640 [MþH]þ, found 440.1639.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(cyclohexylmethyl)-3-
(6-methylbenzo[d] thiazol-2-yl)urea (18b): 1H NMR (DMSO-d6,
300 MHz), d: 9.93 (s, 1H, CONH), 7.56 (s, 1H, ArH),
7.12–7.20 (m, 3H, ArH), 6.95–6.97 (m, 3H, ArH), 4.80
(s, 2H, COCH2), 4.19 (q, 2H, J¼7.2 Hz, CH2), 3.56
(d, 2H, J¼6.9 Hz, CH2), 2.34 (s, 1H, CH3), 1.56–1.66
(m, 4H, CH2 2), 1.41 (m, 1H, CH¼), 1.22 (t, 3H,
J¼6.9 Hz, CH3), 1.09–1.18 (m, 4H, CH2 2), 0.88–0.93
(m, 2H, CH2); m/z 482.2 [MþH]þ; HR-MS calculated for
C26H31N3O4S: m/z 482.2115 [MþH]þ, found 482.2108.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-butyl)-3-(6-methy
lbenzo[d]thiazol-2-yl) urea (18c): 1H NMR (DMSO-d6,
300 MHz), d: 7.58 (s, 1H, ArH), 7.29 (s, 1H, ArH), 7.22
(d, 2H, J¼3.6 Hz, ArH), 7.14 (d, 1H, J¼3.6 Hz, ArH), 4.80
(s, 2H, COCH2), 4.22 (q, 2H, J¼6.9 Hz, CH2), 2.34
(s, 3H, CH3), 1.43 (t, 2H, J¼6.9 Hz, CH2), 1.301.20
(m, 5H, CH2CH3), 0.87 (t, 3H, J¼6.9 Hz, CH3); m/z 441.2
[MþH]þ; HR-MS calculated for C23H27N3O4S: m/z 422.1795
[MþH]þ, found 422.1804.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-
(6-methylbenzo[d]thiazol-2-yl) urea (18d): 1H NMR
(DMSO-d6, 300 MHz), d: 10.08 (s, 1H, CONH), 7.58 (s,
1H, ArH), 7.29 (s, 1H, ArH), 7.20 (d, 2H, J¼8.7 Hz, ArH),
7.12 (d, 1H, J¼8.4 Hz, ArH), 6.96 (d, 2H, J¼9 Hz, ArH),
4.80 (s, 2H, COCH2), 4.18 (q, 2H, J¼6.9 Hz, CH2),
3.65 (t, 2H, J¼7.2 Hz, CH2), 2.34 (s, 3H, CH3), 1.44
(m, 2H, CH2), 1.14–1.29 (m, 7H, CH2 2, CH3), 0.83
(t, 3H, J¼6.9 Hz, CH3); m/z 456 [MþH]þ; HR-MS calcu-
lated for C24H29N3O4S: m/z 456.1955 [MþH]þ, found
456.1952.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(i-pentyl)-3-(6-me-
thylbenzo[d]thiazol-2-yl) urea (18e): 1H NMR (DMSO-d6,
300 MHz), d: 7.58 (s, 1H, ArH), 7.18–7.28 (m, 3H, ArH), 7.12
(d, 1H, J¼7.5 Hz, ArH), 6.96 (d, 2H, J¼8.7 Hz, ArH), 4.80
(s, 2H, COCH2), 4.17 (q, 2H, J¼7.2 Hz, CH2), 3.68 (t,
2H, J¼7.2 Hz, CH2), 2.34 (s, 3H, CH3), 1.48–1.59 (m,
1H, CH¼), 1.371.30 (m, 2H, CH2), 1.22 (t, 3H,
J¼6.9 Hz, CH3), 0.83 (d, 6H, J¼6.9 Hz, CH3 2); m/z456.2 [MþH]þ; HR-MS calculated for C24H29N3O4S: m/z
456.1944 [MþH]þ, found 456.1952.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(3-methyl-2-bute-
nyl)-3-(6-methylbenzo[d] thiazol-2-yl)urea (18f): 1H NMR
(DMSO-d6, 300 MHz), d: 10.04 (s, 1H, CONH), 7.58 (s,
1H, ArH), 7.28–7.11 (m, 4H, ArH), 6.93 (d, 2H, J¼8.4 Hz,
ArH), 5.22 (t, 1H, J¼6.9 Hz, CH¼ ), 4.79 (s, 2H,
COCH2), 4.14–4.27 (m, 4H, CH2 2), 2.34 (s, 3H,
CH3), 1.62 (s, 3H, CH3), 1.44 (s, 3H, CH3), 1.20 (t, 3H,
J¼6.9 Hz, CH3); m/z 454 [MþH]þ; HR-MS calculated for
C24H27N3O4S: m/z 454.1792 [MþH]þ, found 454.1795.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(pyri-
dine-2-yl)urea (19a): 1H NMR (DMSO-d6, 300 MHz), d:
8.07 (m, 1H, ArH), 7.94 (d, 1H, J¼8.7 Hz ArH), 7.64–7.73
(m, 1H, ArH), 7.32 (d, 2H, J¼8.7 Hz, ArH), 7.06 (d, 2H,
J¼8.7 Hz, ArH), 7.04 (s, 1H, CONH) 6.93–6.97 (m, 1H,
ArH), 4.84 (s, 2H, COCH2), 4.19 (t, 2H, J¼6.6 Hz,
CH2), 3.60 (t, 2H, J¼7.2 Hz, CH2), 1.40–1.45 (m,
2H, CH2), 1.21–1.40 (m, 4H, CH2 2), 1.19–1.32 (m,
3H, CH3), 0.83 (t, 3H, J¼6.9 Hz, CH3); m/z 386 [MþH]þ;
HR-MS calculated for C21H27N3O4: m/z 386.2063 [MþH]þ,
found 386.2074.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-methyl-
pyridine-2-yl)urea (19b): 1H NMR (DMSO-d6, 300 MHz), d: 7.90
(m, 1H, ArH), 7.84 (d, 1H, J¼8.7 Hz, ArH), 7.52 (dd, 1H,
J1¼2.1 Hz, J2¼8.4 Hz, ArH), 7.30 (d, 2H, J¼8.7 Hz, ArH), 7.05
(d, 2H, J¼8.7 Hz, ArH), 6.97 (s, 1H, CONH), 4.84 (s, 2H,
COCH2), 4.18 (q, 2H, J¼6.9 Hz, CH2), 3.60 (t, 2H,
J¼6.9 Hz, CH2), 2.16 (s, 3H, CH3), 1.40–1.44 (m, 2H,
CH2), 1.251.18 (m, 7H, CH2 2, CH3), 0.82 (t, 3H,
J¼6.9 Hz, CH3); m/z 400 [MþH]þ; HR-MS calculated for
C22H29N3O4: m/z 400.222 [MþH]þ, found 400.2231.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-chlo
ropyridine-2-yl)urea (19c): 1H NMR (DMSO-d6, 300 MHz), d:
8.18–8.22 (dd, 1H, J1¼0.6 Hz, J2¼2.4 Hz, ArH), 7.96 (d, 1H,
J¼9.0 Hz, ArH), 7.81 (dd, 1H, J1¼2.4 Hz, J2¼9.0 Hz, ArH),
7.29–7.32 (m, 3H, ArH, CONH), 7.04 (d, 2H, J¼9.0 Hz,
ArH), 4.83 (s, 2H, COCH2), 4.18 (q, 2H, J¼6.9 Hz,
CH2), 3.60 (t, 2H, J¼7.2 Hz, CH2), 1.40–1.44 (m,
2H, CH2), 1.25–1.18 (m, 7H, CH2 2, CH3), 0.83 (t,
3H, J¼6.6 Hz, CH3); m/z 420 [MþH]þ; HR-MS calculated
for C22H26ClN3O4: m/z 420.1679 [MþH]þ, found 460.1685.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-
methoxylformylpyridine-2-yl) urea (19d): 1H NMR (DMSO-
d6, 300 MHz), d: 8.63 (d, 1H, J¼2.1 Hz, ArH), 8.18–8.22 (dd,
1H, J1¼2.1 Hz, J2¼8.7 Hz, ArH), 8.06 (d, 1H, J¼8.7 Hz,
ArH), 7.60 (s, 1H, CONH), 7.32 (d, 2H, J¼8.7 Hz, ArH),
7.05 (d, 2H, J¼8.7 Hz, ArH), 4.84 (s, 2H, COCH2), 4.14–
4.21 (q, 2H, J¼6.9 Hz, CH2), 3.81 (s, 3H, OCH3), 3.62
(t, 2H, J¼7.5 Hz, CH2), 1.41–1.46 (m, 2H, CH2), 1.14–
1.26 (m, 7H, CH2 2, CH3), 0.83 (t, 3H, J¼6.9 Hz,
CH3); m/z 444.2 [MþH]þ; HR-MS calculated for
C23H29N3O6: m/z 444.2114 [MþH]þ, found 444.2129.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-
ethoxylformylpyridine-2-yl) urea (19e): 1H NMR (DMSO-
d6, 300 MHz), d: 8.62 (s, 1H, ArH), 8.33 (d, 1H, J¼8.7 Hz,
ArH), 8.06 (d, 1H, J¼9.0 Hz, ArH), 7.60 (s, 1H, CONH),
7.32 (d, 2H, J¼8.4 Hz, ArH), 7.05 (d, 2H, J¼8.4 Hz, ArH),
4.84 (s, 2H, COCH2), 4.24–4.31 (q, 2H, J¼7.2 Hz,
CH2), 4.14–4.21 (q, 2H, J¼6.9 Hz, CH2), 3.62 (t, 2H,
J¼6.6 Hz, CH2), 1.44 (m, 2H, CH2), 1.18–1.30 (m,
10H, CH2 2, CH3 2), 0.83 (t, 3H, J¼6.9 Hz, CH3);
Lijian Zhang et al.596m/z 458.2 [MþH]þ; HR-MS calculated for C24H31N3O6: m/z
458.228 [MþH]þ, found 458.2286.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-iso
propoxylformylpyridine-2-yl)urea (19f): 1H NMR (DMSO-d6,
300 MHz), d: 8.60 (d, 1H, J¼1.5 Hz, ArH), 8.16–8.20 (dd, 1H,
J1¼2.1 Hz, J2¼8.7 Hz, ArH), 8.05 (d, 1H, J¼8.7 Hz, ArH),
7.60 (s, 1H, CONH), 7.32 (d, 2H, J¼8.7 Hz, ArH), 7.05
(d, 2H, J¼8.7 Hz, ArH), 5.10 (m, 1H, CH¼), 4.84
(s, 2H, COCH2), 4.14–4.21 (q, 2H, J¼6.9 Hz, CH2),
3.62 (t, 2H, J¼7.5 Hz, CH2), 1.44 (m, 2H, CH2), 1.14–
1.26 (m, 13H, CH2 2, CH3 3), 0.83 (t, 3H, J¼6.9
Hz, CH3); m/z 472.2 [MþH]þ; HR-MS calculated for
C25H33N3O6: m/z 472.2445 [MþH]þ, found 472.2442.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-meth
ylthiazol-2-yl)urea (19g): 1H NMR (DMSO-d6, 300 MHz), d:
9.63 (s, 1H, CONH), 7.18 (d, 2H, J¼8.7 Hz, ArH), 6.95
(d, 2H, J¼8.7 Hz, ArH), 6.48 (s, 1H, ArH), 4.79
(s, 2H, COCH2), 4.17 (q, 2H, J¼6.9 Hz, CH2), 3.61
(t, 2H, J¼7.5 Hz, CH2), 2.12 (s, 3H, CH3) 1.40–1.50
(m, 2H, CH2), 1.241.14 (m, 7H, CH2 2, CH3),
0.80–0.84 (t, 3H, J¼6.9 Hz, CH3); m/z 406.2 [MþH]þ; HR-
MS calculated for C20H27N3O4S: m/z 406.1786 [MþH]þ, found
406.1795.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-
(5-chlorothiazol-2-yl)urea (19h): 1H NMR (DMSO-d6,
300 MHz), d: 10.34 (s, 1H, CONH), 7.40 (s, 1H, ArH),
7.20 (d, 2H, J¼8.7 Hz, ArH), 6.81 (d, 2H, J¼8.7 Hz, ArH),
4.80 (s, 2H, COCH2), 4.17 (q, 2H, J¼6.9 Hz, CH2),
3.60 (t, 2H, J¼7.5 Hz, CH2), 1.40–1.50 (m, 2H, CH2),
1.24–1.33 (m, 7H, CH2 2, CH3), 0.80–0.84
(t, 3H, J¼6.9 Hz, CH3); m/z 426.1 [MþH]þ; HR-MS
calculated for C19H24ClN3O4S: m/z 426.1245 [MþH]þ, found
426.1249.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-
(5-ethoxylformylthiazol-2-yl)urea (19i): 1H NMR
(DMSO-d6, 300 MHz), d: 10.54 (s, 1H, CONH), 7.85 (s,
1H, ArH), 7.20 (d, 2H, J¼8.7 Hz, ArH), 6.97 (d, 2H, J¼8.7
Hz, ArH), 4.80 (s, 2H, COCH2), 4.14–4.26 (m, 4H,
CH2 2), 3.61 (t, 2H, J¼7.2 Hz, CH2), 1.42 (m, 2H,
CH2), 1.14–1.30 (m, 10H, CH2 2, CH3 2), 0.80–
0.84 (t, 3H, J¼6.9 Hz, CH3); m/z 464.2 [MþH]þ; HR-MS
calculated for C22H29N3O6S: m/z 464.1855 [MþH]þ, found
464.1850.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(benzo
[d]thiazol-2-yl)urea (19j): 1H NMR (DMSO-d6, 300 MHz), d:
10.24 (s, 1H, CONH), 7.78 (d, 1H, J¼7.5 Hz, ArH),
7.397.29 (m, 2H, ArH), 7.227.15 (m, 3H, ArH), 6.96 (d,
2H, J¼8.4 Hz, ArH), 4.80 (s, 2H, COCH2), 4.15–4.22 (q,
2H, J¼6.9 Hz, CH2), 3.66 (t, 2H, J¼7.2 Hz, CH2), 1.44
(m, 2H, CH2), 1.16–1.29 (m, 7H, CH2 2, CH3), 0.83
(t, 3H, J¼6.9 Hz, CH3); m/z 442 [MþH]þ; HR-MS calculated
for C23H27N3O4S: m/z 442.1789 [MþH]þ, found 442.1795.
1-[4-(2-Ethoxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(6-metho
xylbenzo[d]thiazol-2-yl) urea (19k): 1H NMR (DMSO-d6,
300 MHz), d: 10.05 (s, 1H, CONH), 7.43 (s, 1H, ArH),
7.33 (m, 1H, ArH), 7.21 (d, 2H, J¼8.7 Hz, ArH), 6.90–6.98
(m, 3H, ArH), 4.80 (s, 2H, COCH2), 4.15–4.22 (q, 2H,
J¼6.9 Hz, CH2), 3.76 (s, 3H, OCH3), 3.65 (t, 2H,
J¼7.2 Hz, CH2), 1.44 (m, 2H, CH2), 1.16–1.25 (m,
7H, CH2 2, CH3), 0.83 (t, 3H, J¼6.9 Hz, CH3); m/z
472 [MþH]þ; HR-MS calculated for C24H29N3O5S: m/z
472.1906 [MþH]þ, found 472.1901.1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-
(pyridine-2-yl)urea (20a): 1H NMR (DMSO-d6, 300 MHz),
d: 8.07 (m, 1H, ArH), 7.94 (d, 1H, J¼8.7 Hz, ArH), 7.67–7.72
(m, 1H, ArH), 7.29 (d, 2H, J¼8.7 Hz, ArH), 6.98 (s, 1H,
CONH), 6.92–7.02 (m, 3H, ArH), 4.57 (s, 2H,
COCH2), 3.59 (t, 2H, J¼7.5 Hz, CH2), 1.43 (m, 2H,
CH2), 1.23–1.25 (m, 4H, CH2 2), 0.83 (t, 3H, J¼6.9
Hz, CH3); m/z 358 [MþH]þ; HR-MS calculated for
C19H23N3O4: m/z 358.1763 [MþH]þ, found 358.1761.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-
methylpyridine-2-yl)urea (20b): 1H NMR (DMSO-d6,
300 MHz), d: 13.03 (s, 1H, OH), 7.90 (m, 1H, ArH), 7.83
(d, 1H, J¼8.4 Hz, ArH), 7.53 (dd, 1H, J1¼2.1 Hz, J 2¼
8.4 Hz, ArH), 7.30 (d, 2H, J¼9.0 Hz, ArH), 7.01–7.04 (m, 3H,
ArH, CONH), 4.73 (s, 2H, COCH2), 3.59 (t, 2H,
J¼7.2 Hz, CH2), 2.16 (s, 1H, CH3), 1.40–1.44 (m, 2H,
CH2), 1.24 (m, 4H, CH2 2), 0.82 (t, 3H, J¼6.6 Hz,
CH3); m/z 372.2 [MþH]þ; HR-MS calculated for
C20H25N3O4: m/z 372.191 [MþH]þ, found 372.1918.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-
chloropyridine-2-yl)urea (20c): 1H NMR (DMSO-d6,
300 MHz), d: 13.05 (s, 1H, OH), 8.13 (d, J¼2.7 Hz, ArH),
7.97 (d, 1H, J¼9.0 Hz, ArH), 7.82 (dd, 1H, J1¼2.7 Hz,
J2¼9.0 Hz, ArH), 7.29–7.32 (m, 3H, ArH, CONH), 7.02
(d, 2H, J¼8.7 Hz, ArH), 4.73 (s, 2H, COCH2), 3.60 (t, 2H,
J¼7.2 Hz, CH2), 1.43 (m, 2H, CH2), 1.24 (m, 4H,
CH2 2), 0.83 (t, 3H, J¼6.6 Hz, CH3); m/z 392
[MþH]þ; HR-MS calculated for C19H22ClN3O4: m/z
392.1373 [MþH]þ, found 392.1372.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-
hydroxylformylpyridine-2-yl)urea (20d): 1H NMR (DMSO-d6,
300 MHz), d: 13.03 (s, 2H, OH 2), 8.64 (d, 1H, J¼2.1 Hz,
ArH), 8.20 (m, 1H, ArH), 8.05 (d, 1H, J¼8.7 Hz, ArH), 7.52
(s, 1H, CONH), 7.32 (d, 2H, J¼8.7 Hz, ArH), 7.03 (d, 2H,
J¼8.7 Hz, ArH), 4.74 (s, 2H, COCH2), 3.62 (t, 2H,
J¼6.9 Hz, CH2), 1.44 (m, 2H, CH2), 1.24 (m, 4H,
CH2 2), 0.83 (t, 3H, J¼6.9 Hz, CH3); m/z 402
[MþH]þ; HR-MS calculated for C20H23N3O6: m/z 402.1669
[MþH]þ, found 402.1660.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(thia-
zol-2-yl)urea (20e): 1H NMR (DMSO-d6, 300 MHz), d: 7.25
(d, 1H, J¼3.9 Hz, ArH), 7.20 (d, 2H, J¼8.7 Hz ArH), 6.94–
6.98 (m, 3H, ArH), 4.70 (s, 2H, COCH2), 3.62 (t, 2H,
J¼6.9 Hz, CH2), 1.42 (m, 2H, CH2), 1.21–1.24 (m, 4H,
CH2 2), 0.82 (t, 3H, J¼6.9 Hz, CH3); m/z 364
[MþH]þ; HR-MS calculated for C17H21N3O4S: m/z 364.1329
[MþH]þ, found 364.1326.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-
(5-methylthiazol-2-yl)urea (20f): 1H NMR (DMSO-d6,
300 MHz), d: 7.18 (d, 2H, J¼8.7 Hz, ArH), 6.93 (d, 2H,
J¼8.7 Hz, ArH), 6.48 (s, 1H, ArH), 4.69 (s, 2H, COCH2),
3.60 (t, 2H, J¼6.9 Hz, CH2), 2.12 (s, 3H, CH3), 1.42
(m, 2H, CH2), 1.231.21 (m, 4H, CH2 2), 0.82
(t, 3H, J¼6.9 Hz, CH3); m/z 378 [MþH]þ; HR-MS calcu-
lated for C18H23N3O4S: m/z 378.1496 [MþH]þ, found
378.1482.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-chlor-
othiazol-2-yl)urea (20g): 1H NMR (DMSO-d6, 300 MHz), d:
10.35 (s, 1H, CONH), 7.32 (s, 1H, ArH), 7.20 (d, 2H,
J¼8.7 Hz, ArH), 6.94 (d, 2H, J¼8.7 Hz, ArH), 4.69 (s, 2H,
COCH2), 3.60 (t, 2H, J¼7.5 Hz, CH2), 1.42 (m, 2H,
CH2), 1.24–1.23 (m, 4H, CH2 2), 0.80–0.84 (t, 3H,
Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARg 597J¼6.9 Hz, CH3); m/z 398 [MþH]þ; HR-MS calculated for
C17H20ClN3O4S: m/z 398.0927 [MþH]þ, found 398.0936.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(5-hydro-
xylformylthiazol-2-yl) urea (20h): 1H NMR (DMSO-d6,
300 MHz), d: 12.84 (s, 2H, COOH 2), 10.38 (s, 1H,
CONH), 7.82 (s, 1H, ArH), 7.20 (d, 2H, J¼8.7 Hz,
ArH), 6.95 (d, 2H, J¼8.7 Hz, ArH), 4.69 (s, 2H, COCH2),
3.63 (t, 2H, J¼7.2 Hz, CH2), 1.43 (m, 2H, CH2), 1.14–
1.28 (m, 4H, CH2 2), 0.80–0.84 (t, 3H, J¼6.9 Hz,
CH3); m/z 408 [MþH]þ; HR-MS calculated for
C18H21N3O6S: m/z 408.1216 [MþH]þ, found 408.1224.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-
(benzo[d]thiazol-2-yl)urea (20i): 1H NMR (DMSO-d6,
300 MHz), d: 7.78 (d, 1H, J¼7.5 Hz, ArH), 7.39–7.29 (m,
2H, ArH), 7.22–7.15 (m, 3H, ArH), 6.96 (d, 2H, J¼8.4 Hz,
ArH), 4.80 (s, 2H, COCH2), 4.15–4.20 (q, 2H, J¼6.9 Hz,
CH2), 3.66 (t, 2H, J¼7.2 Hz, CH2), 1.45 (m, 2H,
CH2), 1.24–1.25 (m, 4H, CH2 2 ), 0.83 (t, 3H,
J¼6.9 Hz, CH3); m/z 414 [MþH]þ; HR-MS calculated for
C21H23N3O4S: m/z 414.1486 [MþH]þ, found 414.1482.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(6-
methylbenzo[d]thiazol-2-yl)urea (20j): 1H NMR (DMSO-d6,
300 MHz), d: 7.58 (s, 1H, ArH), 7.27 (s, 1H, ArH), 7.20 (d,
2H, J¼8.7 Hz, ArH), 7.12 (d, 1H, J¼7.8 Hz, ArH), 6.94 (d,
2H, J¼8.7 Hz, ArH), 4.70 (s, 2H, COCH2), 3.65 (t, 2H,
J¼7.2 Hz, CH2), 2.34 (s, 3H, CH3), 1.45 (m, 2H,
CH2), 1.24–1.29 (m, 4H, CH2 2), 0.83 (t, 3H, J¼6.9
Hz, CH3); m/z 428 [MþH]þ; HR-MS calculated for
C22H25N3O4S: m/z 428.1639 [MþH]þ, found 428.1639.
1-[4-(2-Hydroxyl-2-oxoethoxy)phenyl]-1-(n-pentyl)-3-(6-
methoxylbenzo[d]thiazol-2-yl)urea (20k): 1H NMR (DMSO-
d6, 300 MHz), d: 7.42 (s, 1H, ArH), 7.34 (m, 1H, ArH), 7.21 (d,
2H, J¼8.7 Hz, ArH), 6.90–6.96 (m, 3H, ArH), 4.70 (s, 2H,
COCH2), 3.76 (s, 3H, OCH3), 3.65 (t, 2H, J¼7.2 Hz,
CH2), 1.44 (m, 2H, CH2), 1.24–1.25 (m, 4H, CH2 2),
0.83 (t, 3H, J¼6.9 Hz, CH3); m/z 444 [MþH]þ; HR-MS
calculated for C22H25N3O5S: m/z 444.1593 [MþH]þ, found
444.1588.
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